Zobrazeno 1 - 10
of 92
pro vyhledávání: ''
Autor:
Neal D. Shore, Joyce Steinberg, Bertrand Tombal, Ugo De Giorgi, Xun Lin, Qi Shen, Fred Saad, David F. Penson, Katarzyna Madziarska, Jennifer Sugg, Cora N. Sternberg, Eleni Efstathiou, Maha Hussain, Karim Fizazi
Publikováno v:
European journal of cancer, Vol. 159, p. 237-246 (2021)
BACKGROUND: Enzalutamide combined with androgen deprivation therapy (ADT) significantly prolonged metastasis-free survival and overall survival (OS) versus ADT alone in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) with r
Autor:
Guilherme Cantuaria, Paul DiSilvestro, Kirsty Rhodes, Lucy Gilbert, Johanna Mäenpää, Christian Marth, Maria Jesus Rubio Pérez, Koji Matsumoto, Claire Garnier-Tixidre, Ayumi Shikama, Isabelle Ray-Coquard, Philipp Harter, Daniel M. Anderson, Magdalena Sikorska, Francesco Raspagliesi, Ignace Vergote, Mario Ouwens, Robert Hettle, Domenica Lorusso, Kathleen N. Moore, Andres Poveda, Nicoletta Colombo, Ronnie Shapira-Frommer
Publikováno v:
European Journal of Cancer. 157:415-423
BACKGROUND: In the absence of randomised head-to-head trials, we conducted a population-adjusted indirect treatment comparison (PA-ITC) of phase III trial data to evaluate the relative efficacy and safety of maintenance olaparib and bevacizumab alone
Autor:
Shi Ming Tu, Sumit K. Subudhi, Ana Aparicio, Ioannis Alafis, Brian F. Chapin, Xuemei Wang, Myrto Boukovala, Paul G. Corn, Nicholas Spetsieris, John C. Araujo, Justin A. Weldon, Eleni Efstathiou, Jennifer Wang, Lisa Pruitt, Christopher J. Logothetis, Amado J. Zurita, John Papadopoulos, John J. Davis
Publikováno v:
European Journal of Cancer. 157:259-267
Background Intermittent androgen deprivation therapy (ADT) in biochemically recurrent castration-naive prostate cancer is non-inferior to continuous therapy. We hypothesised that finite-duration abiraterone acetate plus prednisone (Abi +P) added to A
Autor:
Minghua Ge, Yan-Yan Liu, Zhengdong Li, Liangfang Shen, Qingyuan Zhang, Yi Luo, Jifeng Feng, Ye Guo, W. Chen, Kun-Yu Yang, Xiaohui He, Kai Xue, Yan Sun, T. Lin, Xiao-Dong Zhu, Xiao Ming Huang, XinYing Chang, Chunmei Bai, Yan Zeng, Lin Wang
Publikováno v:
European Journal of Cancer. 156:35-45
Background The EXTREME regimen (chemotherapy [CT; cisplatin/carboplatin and 5-fluorouracil]) plus cetuximab is a standard-of-care first-line (1L) treatment for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/
Autor:
Mateusz Opyrchal, Kian-Huat Lim, Jace Webster, Saiama N. Waqar, Albert C. Lockhart, Ningying Wu, Christopher G. Maher, Nick Boice, Joel Picus, Andrea Wang-Gillam, Benjamin R. Tan, Feng Gao, Maria Q. Baggstrom, Abhi Acharya, Daniel Morgensztern, Ramaswamy Govindan
Publikováno v:
European Journal of Cancer. 154:102-110
Aim Aurora kinase A (AURKA) is a pleiotropic serine/threonine kinase that orchestrates mitotic progression. Paclitaxel stabilises microtubules and disrupts mitotic spindle assembly. The combination of AURKA inhibitor (alisertib) plus paclitaxel may b
Autor:
Ugo De Giorgi, Giovanni Bozza, Roberto Sabbatini, Maurizio Nicodemo, Massimo Aglietta, Sabrina Rossetti, Franco Morelli, Giovanni L. Pappagallo, Giovanni Re, Camillo Porta, Giorgia Razzini, Lucia Fratino, Gaetano Facchini, Michele Aieta, Alessandro D'Angelo, Francesco Carrozza, Marco Maruzzo, Orazio Caffo, Paola Ermacora, Isabella Vittimberga, Erica Palesandro, Stefania Kinspergher, Sebastiano Buti, Monica Giordano, Daniela Scapoli, Franco Nolè, Luca Galli, Claudia Mucciarini, Donatello Gasparro, Cinzia Ortega, Chiara Ciccarese, Elena Verri, Francesca Maines, Giuseppe Schepisi, Francesca Valcamonico, Roberto Iacovelli, Antonello Veccia, Vittorina Zagonel, Caterina Messina, Donata Sartori, Paolo Lippe
Publikováno v:
European Journal of Cancer. 155:56-63
Background Pre-clinical data suggest that docetaxel and enzalutamide interfere with androgen receptor translocation and signalling. The aim of this study is to assess the efficacy of their concurrent administration in the first-line treatment for met
Autor:
Shunichi Sugawara, Junji Kishimoto, Hajime Asahina, Kenji Sugio, Yukari Tsubata, Yoshihiro Miyata, Kana Watanabe, Kosuke Hamai, Taishi Harada, Takahiro Uchida, Isamu Okamoto, Satoshi Oizumi, Kentaro Tanaka, Kunihiko Kobayashi
Publikováno v:
European Journal of Cancer. 149:14-22
Background Osimertinib is now a standard treatment for patients with previously untreated EGFR-mutated advanced non–small cell lung cancer (NSCLC). We here investigated whether the combination of osimertinib with cytotoxic chemotherapy might hold a
Autor:
Jie Xiang, Jian Li, Chengqiang Li, Yuyan Zheng, Shengguang Zhao, Hecheng Li, Kai Chen, Yichao Han, Zenghui Cheng, Yuquan Wu, Xiaoyan Chen, Toni Lerut, Xi-Jia Feng, Weixiang Qi
Publikováno v:
European Journal of Cancer. 144:232-241
Background To investigate the safety and activity of preoperative pembrolizumab combined with chemoradiotherapy for resectable oesophageal squamous cell carcinoma (ESCC) ( ClinicalTrials.gov number, NCT03792347). Methods Twenty resectable ESCC patien
Autor:
Laetitia Dahan, Romain Cohen, Meher Ben Abdelghani, Hélène Castanié, Christophe Tournigand, Jean-Philippe Metges, Paul Gougis, Anthony Turpin, Cindy Neuzillet, Jean-Frédéric Blanc, Dewi Vernerey, David Tougeron, Benoit Rousseau, Marc Hilmi, Marie-Line Garcia-Larnicol, Alice Boilève
Publikováno v:
European Journal of Cancer. 143:55-63
Background The IMMUNOBIL PRODIGE 57 trial is a non-comparative randomized phase II study assessing the efficacy and safety of the durvalumab (an anti-PD-L1) and tremelimumab (an anti-CTLA4) combination with or without weekly paclitaxel in patients wi
Autor:
Didier Debieuvre, Pierre-Jean Souquet, Jean-Louis Pujol, Jérôme Dauba, Jeannick Madelaine, Olivier Molinier, J. Otto, Jacques Le Treut, Fabrice Barlesi, Elisabeth Quoix, Patrick Aldo Renault, Eric Pichon, Alexandra Langlais, Virginie Westeel, L. Moreau, Franck Morin, Jacques Margery, Clarisse Audigier-Valette, Armelle Lavolé, Patrick Dumont, Denis Moro-Sibilot
Publikováno v:
European Journal of Cancer
European Journal of Cancer, 2020, 138, pp.193-201. ⟨10.1016/j.ejca.2020.07.034⟩
European Journal of Cancer, Elsevier, 2020, 138, pp.193-201. ⟨10.1016/j.ejca.2020.07.034⟩
European Journal of Cancer, 2020, 138, pp.193-201. ⟨10.1016/j.ejca.2020.07.034⟩
European Journal of Cancer, Elsevier, 2020, 138, pp.193-201. ⟨10.1016/j.ejca.2020.07.034⟩
International audience; Purpose: Maintenance chemotherapy is a reasonable choice for patients with metastatic non-small cell lung carcinoma (NSCLC) not progressing after induction therapy with a platinum-based doublet. Nevertheless, there have been n